Does Myo-Inositol Sleep Randomized Trial work?

Updated July 2026

Quick Answer

Myo-Inositol Sleep Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: The global prevalence of PCOS increased from 36.7 to 69.5 million between 1990 and 2021.

Key Takeaways

  • 01The global prevalence of PCOS increased from 36.7 to 69.5 million between 1990 and 2021. [Subakathulla Sumayyah (2026)]
  • 02Emerging evidence underscores that OS is not a mere byproduct of metabolic imbalance but a central driver that disrupts insulin signaling, amplifies androgen biosynthesis, and impairs folliculogenesis (,). [Subakathulla Sumayyah (2026)]
  • 03Low-dose variants of OCPs have been observed with an increased risk of myocardial infarction and cardiovascular arterial disease (). [Subakathulla Sumayyah (2026)]
  • 041 2 3 4 5 Polycystic ovary syndrome (PCOS) represents one of the most complex endocrine-metabolic disorders affecting women of reproductive age, characterized by a collection of reproductive, metabolic, and psychological manifestations (,). [Subakathulla Sumayyah (2026)]
The current Migaku evidence database contains 2 reusable source documents for Myo-Inositol Sleep Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - The global prevalence of PCOS increased from 36.7 to 69.5 million between 1990 and 2021. [Subakathulla Sumayyah (2026); evidence level 3] - Emerging evidence underscores that OS is not a mere byproduct of metabolic imbalance but a central driver that disrupts insulin signaling, amplifies androgen biosynthesis, and impairs folliculogenesis (,). [Subakathulla Sumayyah (2026); evidence level 3] - Low-dose variants of OCPs have been observed with an increased risk of myocardial infarction and cardiovascular arterial disease (). [Subakathulla Sumayyah (2026); evidence level 3] - 1 2 3 4 5 Polycystic ovary syndrome (PCOS) represents one of the most complex endocrine-metabolic disorders affecting women of reproductive age, characterized by a collection of reproductive, metabolic, and psychological manifestations (,). [Subakathulla Sumayyah (2026); evidence level 3] - Anxiety and depressive disorders frequently co-occur, and converging evidence from symptom profiles, longitudinal course, shared neurobiological markers, familial aggregation, and treatment response supports a substantial overlap between these conditions []. [Derkaczew Maria (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails?
  2. Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review